These results demonstrate that TDP-43 is an effective therapeutic target for ALS/FTD, indicating the possibility of the establishment of disease-modifying therapies using TDP-43-targeting ASOs that would suppress the onset or delay the progression of TDP-43 proteinopathies, including ALS/FTD. The gene discussed is TARDBP; the disease is proteostasis deficiencies.